United Therapeutics Stock Analysis

United Stock Analysis Notes

About 100.0% of the company outstanding shares are owned by institutional investors. The book value of United Therapeutics was at this time reported as 136.74. The company has Price/Earnings To Growth (PEG) ratio of 1.43. United Therapeutics recorded earning per share (EPS) of 22.77. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 23rd of September 2009. United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. United Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 965 people. For more information please call the company at 301 608 9292 or visit https://www.unither.com.

United Therapeutics Investment Alerts

United Therapeutics Upcoming and Recent Events

United Largest EPS Surprises

View All Earnings Estimates

United Therapeutics Environmental, Social, and Governance (ESG) Scores

United Stock Institutional Investors

Note, although United Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

United Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 16.64 B.

United Profitablity

The company has Profit Margin (PM) of 0.4 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.55 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.55.

Management Efficiency

United Therapeutics has return on total asset (ROA) of 0.1189 % which means that it generated a profit of $0.1189 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1881 %, meaning that it created $0.1881 on every $100 dollars invested by stockholders. United Therapeutics' management efficiency ratios could be used to measure how well United Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, United Therapeutics' Return On Capital Employed is relatively stable compared to the past year. As of 01/30/2025, Return On Assets is likely to grow to 0.13, while Return On Tangible Assets are likely to drop 0.13. At this time, United Therapeutics' Intangibles To Total Assets are relatively stable compared to the past year. As of 01/30/2025, Debt To Assets is likely to grow to 0.10, while Other Assets are likely to drop slightly above 284.7 M.

Technical Drivers

As of the 30th of January, United Therapeutics has the Coefficient Of Variation of 1750.75, risk adjusted performance of 0.0531, and Semi Deviation of 1.79. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of United Therapeutics, as well as the relationship between them. Please validate United Therapeutics coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if United Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 352.3 per share. Given that United Therapeutics has jensen alpha of 0.0695, we advise you to double-check United Therapeutics's current market performance to make sure the company can sustain itself at a future point.

United Therapeutics Price Movement Analysis

United Therapeutics Insider Trading Activities

United Therapeutics Outstanding Bonds

United Therapeutics Predictive Daily Indicators

United Therapeutics Corporate Filings

United Therapeutics Forecast Models

United Therapeutics' time-series forecasting models are one of many United Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary United Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how United Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling United shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as United Therapeutics. By using and applying United Stock analysis, traders can create a robust methodology for identifying United entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. United analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. United analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

United Therapeutics stock analysis indicators help investors evaluate how United Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading United Therapeutics shares will generate the highest return on investment. By understating and applying United Therapeutics stock analysis, traders can identify United Therapeutics position entry and exit signals to maximize returns.

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.